NCI/NIH Shared Resources

Program Resources
Biopharmaceutical Development Program  Offers resources for and expertise in the development of investigational biological products that move promising treatments for cancer, rare diseases, HIV/AIDS, and other infectious diseases into clinical trials. 
Cancer Prevention Clinical Trials Network (CP-CTNet) CP-CTNet performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions.
Cancer Systems Biology Consortium (CSBC) The multidisciplinary Cancer Systems Biology Consortium (CSBC), which includes cancer biologists, engineers, mathematicians, physicists, and oncologists, aims to tackle the most perplexing issues in cancer to increase our understanding of tumor biology, treatment options, and patient outcome.
Cooperative Human Tissue Network (CHTN) The CHTN is a unique NCI supported resource that provides human tissues and fluids from routine procedures to investigators who utilize human biospecimens in their research. 
DTP Repository Developmental Therapeutics Program (DTP) supports a number of Repositories for the acquisition, storage and distribution of chemical, and biological samples and standards to researchers worldwide.
Human Cancer Models Initiative (HCMI) The goal of HCMI is to create up to 1,000 patient-derived next-generation cancer models (NGCMs) such as organoids, conditionally reprogrammed cells, neurospheres, or optimal growth condition models as a community resource.
Moonshot Biobank The Cancer Moonshot Biobank is a 5-year project to learn more about cancer with the help of participants who donate samples as they receive treatment.
NCI Formulary A public-private partnership between the NCI and pharmaceutical and biotechnology companies that provides NCI funded main-member ETCTN and NCTN institutions in the United States and their investigators rapid access to agents for cancer clinical trial use or to any investigators for preclinical research.
NCI Liver Cancer Program A multidisciplinary network of researchers and clinicians dedicated to improving early detection, diagnosis, prognosis and treatment of liver cancer.
NCI Patient-Derived Models Repository (PDMR) A national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived organoids (PDOrg).
NCI PREVENT Program A peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials.
NExT Program NExT provides resources for projects focused on developing therapies for unmet medical needs in the area of oncology that are not typically addressed by the private sector. NExT is NOT a grant mechanism.
NIH STRIDES Initiative The STRIDES Initiative aims to help NIH and its institutions accelerate biomedical research by reducing barriers in utilizing commercial cloud services. This initiative aims to harness the power of the cloud to accelerate biomedical discovery. NIH and NIH-funded researchers can take advantage of STRIDES benefits.
The Cancer Imaging Archive (TCIA) TCIA is a service which de-identifies and hosts a large archive of medical images of cancer accessible for public download.
The NCI Program for Natural Product Discovery (NPNPD) A library of partially-purified natural product fractions more amenable for use in high-throughput screening. Publicly accessible, free of charge, and open to screening against all disease targets. Launched in 2019. As of March 2023, 500,000 natural product fractions are available
The Stepping Stones Program This initiative is intended to augment grant-supported programs with access to NCI/DCTD/DTP drug development capabilities to fill knowledge and data gaps, thus enabling these programs to advance and procure additional resources for development toward clinical testing.